id	sid	eid	entity	type
dti-1420	1	1	9drug	CARDINAL
dti-1420	1	2	fragkou1	DATE
dti-1420	1	3	maria souli1	PERSON
dti-1420	1	4	maria theochari2	PERSON
dti-1420	1	5	christina kontopoulou3	PERSON
dti-1420	1	6	loukides4	PERSON
dti-1420	1	7	anna koumarianou2	PERSON
dti-1420	1	8	attikon university hospital	ORG
dti-1420	1	9	kapodistrian university of athens	ORG
dti-1420	1	10	athens	GPE
dti-1420	1	11	greece	GPE
dti-1420	2	1	2fourth department of internal medicine	ORG
dti-1420	2	2	attikon university hospital	ORG
dti-1420	2	3	kapodistrian university of athens	ORG
dti-1420	2	4	athens	GPE
dti-1420	2	5	greece	GPE
dti-1420	3	1	32nd	ORDINAL
dti-1420	3	2	attikon university hospital	ORG
dti-1420	3	3	kapodistrian university of athens	ORG
dti-1420	3	4	athens	GPE
dti-1420	3	5	greece	GPE
dti-1420	4	1	42nd	ORDINAL
dti-1420	4	2	attikon university hospital	ORG
dti-1420	4	3	kapodistrian university of athens	ORG
dti-1420	4	4	athens	GPE
dti-1420	4	5	greece	GPE
dti-1420	6	1	pd-1/pd-l1	FAC
dti-1420	8	1	first	ORDINAL
dti-1420	10	1	2016:10 9–12 doi:10.4137/	MONEY
dti-1420	11	1	february 5, 2016	DATE
dti-1420	12	1	april 14, 2016	DATE
dti-1420	13	1	april 18, 2016	DATE
dti-1420	14	1	anuj chauhan	PERSON
dti-1420	14	2	three	CARDINAL
dti-1420	15	1	454	CARDINAL
dti-1420	19	1	3.0	CARDINAL
dti-1420	24	1	third	ORDINAL
dti-1420	30	1	first	ORDINAL
dti-1420	30	2	pembrolizumab	PERSON
dti-1420	32	1	64-year-old	DATE
dti-1420	32	2	10-day	DATE
dti-1420	32	3	9-day	DATE
dti-1420	32	4	daily	DATE
dti-1420	33	1	nine months earlier	DATE
dti-1420	34	1	two	CARDINAL
dti-1420	34	2	1000 mg/m2	QUANTITY
dti-1420	34	3	zoledronic	NORP
dti-1420	34	4	4 mg	QUANTITY
dti-1420	34	5	every three weeks	DATE
dti-1420	35	1	one month later	DATE
dti-1420	35	2	four	CARDINAL
dti-1420	35	3	3 mg/kg	QUANTITY
dti-1420	35	4	zoledronic	NORP
dti-1420	35	5	4	CARDINAL
dti-1420	35	6	weeks	DATE
dti-1420	36	1	three months later	DATE
dti-1420	36	2	second	ORDINAL
dti-1420	36	3	pembrolizumab	PERSON
dti-1420	37	1	thirteen days	DATE
dti-1420	37	2	fourth	ORDINAL
dti-1420	41	1	75%	PERCENT
dti-1420	42	1	200 mm/hour	QUANTITY
dti-1420	42	2	10,970	CARDINAL
dti-1420	42	3	83.6%	PERCENT
dti-1420	42	4	9.7%	PERCENT
dti-1420	42	5	6.7%	PERCENT
dti-1420	42	6	173	CARDINAL
dti-1420	42	7	0–6  mg/l	ORG
dti-1420	44	1	2	CARDINAL
dti-1420	45	1	three days	DATE
dti-1420	47	1	year	DATE
dti-1420	47	2	2016	CARDINAL
dti-1420	47	3	10	CARDINAL
dti-1420	47	4	pembrolizumab http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com	LAW
dti-1420	47	5	http://creativecommons.org/licenses/by-nc/3.0/	LANGUAGE
dti-1420	47	6	10	CARDINAL
dti-1420	49	1	1	CARDINAL
dti-1420	52	1	60.7%	PERCENT
dti-1420	52	2	28.7%	PERCENT
dti-1420	52	3	cd4+/cd8	ORG
dti-1420	52	4	0.4	CARDINAL
dti-1420	54	1	20 mg	QUANTITY
dti-1420	54	2	two days	DATE
dti-1420	55	1	3	CARDINAL
dti-1420	56	1	three months later	DATE
dti-1420	57	1	five-year	DATE
dti-1420	57	2	ipilimumab	PERSON
dti-1420	57	3	bristol-myers squibb	ORG
dti-1420	57	4	nivolumab	PERSON
dti-1420	57	5	bristol-myers squibb	ORG
dti-1420	57	6	pembrolizumab	PERSON
dti-1420	57	7	merck	ORG
dti-1420	57	8	& dohme corp	ORG
dti-1420	57	9	1	CARDINAL
dti-1420	57	10	the us food and drug administration	ORG
dti-1420	57	11	the european medicines	ORG
dti-1420	57	12	1	CARDINAL
dti-1420	57	13	2	CARDINAL
dti-1420	58	1	mab	PERSON
dti-1420	58	2	survival.10	PRODUCT
dti-1420	58	3	cytotoxicity.11	GPE
dti-1420	58	4	mk-3475	PERSON
dti-1420	58	5	lambrolizumab	PERSON
dti-1420	59	1	28 pm	TIME
dti-1420	59	2	s228p fc	PERSON
dti-1420	63	1	1	CARDINAL
dti-1420	64	1	one month	DATE
dti-1420	68	1	cd4/cd8 t-cell ratio	ORG
dti-1420	68	2	hla-dr	PERSON
dti-1420	68	3	20%–40%	PERCENT
dti-1420	69	1	6–13 weeks	DATE
dti-1420	69	2	8	CARDINAL
dti-1420	69	3	23	CARDINAL
dti-1420	71	1	three	CARDINAL
dti-1420	71	2	7–24.3 months	DATE
dti-1420	71	3	two	CARDINAL
dti-1420	71	4	one	CARDINAL
dti-1420	72	1	two	CARDINAL
dti-1420	72	2	one	CARDINAL
dti-1420	72	3	four weeks	DATE
dti-1420	79	1	first	ORDINAL
dti-1420	79	2	mt	GPE
dti-1420	79	3	mt	GPE
dti-1420	79	4	mt	GPE
dti-1420	80	1	mt	GPE
dti-1420	82	1	1	CARDINAL
dti-1420	83	1	postow ma	PERSON
dti-1420	83	2	callahan mk	PERSON
dti-1420	83	3	wolchok jd	PERSON
dti-1420	84	1	j clin oncol	PERSON
dti-1420	85	1	2015;33(17):1974–1982	CARDINAL
dti-1420	85	2	2	CARDINAL
dti-1420	85	3	national cancer institute	ORG
dti-1420	85	4	u.s.	GPE
dti-1420	87	1	4.0	CARDINAL
dti-1420	88	1	bethesda	ORG
dti-1420	88	2	md	GPE
dti-1420	88	3	nih	ORG
dti-1420	88	4	may 28, 2009	DATE
dti-1420	88	5	june 14, 2010	DATE
dti-1420	89	1	nih	ORG
dti-1420	89	2	09-5410	CARDINAL
dti-1420	90	1	june 2010	DATE
dti-1420	91	1	3	CARDINAL
dti-1420	92	1	mcdermott	PERSON
dti-1420	92	2	hodi fs	PERSON
dti-1420	94	1	2014;40:1056–1064	CARDINAL
dti-1420	95	1	4	CARDINAL
dti-1420	95	2	robert c. immune	PERSON
dti-1420	96	1	semin oncol	PERSON
dti-1420	98	1	5	CARDINAL
dti-1420	98	2	robert c	PERSON
dti-1420	98	3	pembrolizumab versus ipilimumab	PERSON
dti-1420	100	1	2015;372:2521–2532	CARDINAL
dti-1420	100	2	6	CARDINAL
dti-1420	103	1	7	CARDINAL
dti-1420	103	2	jin ht	PERSON
dti-1420	103	3	ahmed r	PERSON
dti-1420	103	4	okazaki t. role of pd-1	ORG
dti-1420	104	1	curr	PERSON
dti-1420	105	1	2011;350:17–37	CARDINAL
dti-1420	106	1	huang x	PERSON
dti-1420	106	2	wang yl	PERSON
dti-1420	107	1	sci u s a. 2009;106:6303–6308.	ORG
dti-1420	108	1	9	CARDINAL
dti-1420	108	2	wu	PERSON
dti-1420	109	1	wu	PERSON
dti-1420	109	2	li l	PERSON
dti-1420	109	3	huang j. pd-l1	PERSON
dti-1420	110	1	plos one	PERSON
dti-1420	111	1	2015;10	CARDINAL
dti-1420	112	1	10	CARDINAL
dti-1420	113	1	pardoll dm	PERSON
dti-1420	115	1	nat rev	PERSON
dti-1420	116	1	2012;12:252–264	CARDINAL
dti-1420	117	1	11	CARDINAL
dti-1420	117	2	rituximab	PERSON
dti-1420	118	1	semin hematol	PERSON
dti-1420	120	1	12	CARDINAL
dti-1420	120	2	2016:10 12	DATE
dti-1420	121	1	hamid o	PERSON
dti-1420	121	2	robert c, daud	PERSON
dti-1420	121	3	lambrolizumab	PERSON
dti-1420	125	1	travis wd	PERSON
dti-1420	126	1	american	NORP
dti-1420	127	1	j respir crit	PERSON
dti-1420	127	2	2013;188:733–748	CARDINAL
dti-1420	128	1	14	CARDINAL
dti-1420	129	1	barker af	PERSON
dti-1420	129	2	bergeron	ORG
dti-1420	131	1	15	CARDINAL
dti-1420	131	2	cordier jf	PERSON
dti-1420	131	3	cryptogenic	ORG
dti-1420	132	1	eur respir	PERSON
dti-1420	132	2	j. 2006;28:422–446	PERSON
dti-1420	133	1	16	CARDINAL
dti-1420	134	1	nishimura k	PERSON
dti-1420	136	1	1992;102:26s–31s. 17	DATE
dti-1420	137	1	kim km	PERSON
dti-1420	137	2	kim hc	PERSON
dti-1420	137	3	jeon kn	PERSON
dti-1420	138	1	j. 2008;49:155–158	ORG
dti-1420	139	1	18	CARDINAL
dti-1420	139	2	nishino m	PERSON
dti-1420	139	3	sholl lm	PERSON
dti-1420	139	4	hodi fs	PERSON
dti-1420	140	1	2015;373:288–290	CARDINAL
dti-1420	141	1	19	CARDINAL
dti-1420	142	1	nakashima k	PERSON
dti-1420	142	2	naito t	GPE
dti-1420	143	1	j thorac oncol	PERSON
dti-1420	144	1	2016;11(3	CARDINAL
dti-1420	144	2	432–433	DATE